WELL Health vs. CloudMD: Which TSX Growth Stock Should You Buy Right Now?

WELL Health and CloudMD are two health-tech stocks that have the potential to deliver outsized gains to long-term investors.

In the past decade, growth stocks have crushed the broader indices, driven by a spectacular bull run in the equity markets. While the COVID-19 pandemic decimated the stock market in early 2020, the snap-back rally pushed major indices to record highs, primarily due to growth stocks in the technology space.

The ongoing pandemic has also acted as a tailwind for several companies, such as WELL Health (TSX: WELL) and CloudMD (TSXV: DOC). The shift towards telehealth solutions has accelerated in the last 15 months due to the need for social distancing and economic lockdowns imposed by several countries. However, this trend is likely to continue in 2021 and beyond, making WELL Health and CloudMD solid long-term bets.

WELL Health has gained 8,700% since IPO

WELL Health has been on an absolute tear since its IPO five years back. WELL stock has returned a staggering 8,700% after it went public, which means a $1,000 investment just after its IPO would be worth close to $88,000 today.

This astonishing growth has been supported by a strong uptick in sales and improvement in profit margins. WELL Health has increased sales from $5.9 million in 2018 to $50.24 million in 2020. Comparatively, its operating loss stood at $2.09 million in 2018, or 35.4% of sales, while in 2020, the company reported an operating loss of $10.4 million, or 20.7% of sales.

WELL Health has aggressively acquired companies in the last two years that have contributed to its top-line growth. After we account for its recent acquisitions of CRH Medical and MyHealth, WELL’s combined pro forma sales will be close to $400 million, while its EBITDA would be $100 million on a run-rate basis.

Analysts tracking WELL stock forecast 2021 sales to rise by 427% to $265 million and by 60% to $423 million in 2022. Its bottom line is also expected to improve from a loss per share of $0.03 in 2020 to earnings per share of $0.06.

WELL Health stock is valued at a price-to-2022-sales multiple of 4.6, which is really cheap considering its growth estimates.

CloudMD stock is valued at a market cap of $535 million

Shares of CloudMD have gained 144% since its IPO in late 2017. However, CMD stock is currently trading 27% below its record high, providing investors an opportunity to buy the dip. In the first quarter of 2021, CloudMD sales were up 187% year over year at $8.8 million. It ended the quarter with a gross margin of 41%, which was attributed to a strong revenue mix.

Similar to WELL Health, CloudMD has also grown inorganically, and the company closed five acquisitions in the March quarter, adding $13 million in annualized sales.

CloudMD has experienced early adoption in its Enterprise Health Solutions division, which has bagged $5 million in new multi-year contracts in the March quarter.

During the earnings call, company CEO Dr. Essam Hamza said, “CloudMD already has a revenue run rate of over $120 million, and through highly profitable acquisitions coupled with organic growth and realization of cost synergies, we expect to be profitable in the second half of 2021.”

The final takeaway

Both WELL Health and CloudMD are exciting bets for investors looking to beat the market. However, if I have to choose a winner, it would have to be WELL Health given its larger revenue base and lower valuation metrics.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Tech Stocks

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

Celestica Raised Its 2027 Outlook After Sales Jumped 83%: Is It Too Late to Buy?

With revenue expected to grow 90% in 2027 and adjusted EPS projected to increase 86%, Celestica’s growth prospects remain compelling.

Read more »

atomic particle
Tech Stocks

Constellation Software in a TFSA: Great Business, but Is the Price Right?

Constellation’s acquisition engine appeals, while a cash-flow valuation check argues for patience.

Read more »

Close up of an egg in a nest of twigs on grass with RRSP written on it symbolizing a RRSP contribution.
Dividend Stocks

The RRSP Deadline Is in March: Why Starting in November Gives You the Advantage

Many investors hold stocks like Shopify Inc (TSX:SHOP) in their RRSPs.

Read more »

man studies at computer
Dividend Stocks

Here Are The 3 Canadian Stocks I’d Tell a New Investor to Buy ASAP

Discover strategies for investing in stocks that can help you thrive in a market filled with volatility and uncertainty.

Read more »

Canada Day fireworks over two Adirondack chairs on the wooden dock in Ontario, Canada
Dividend Stocks

Where to Invest Your $7,000 TFSA Contribution Before 2026 Is Over

Put your $7,000 TFSA contribution to work before 2026 ends. Explore BMO, CN and Constellation Software for income and long-term…

Read more »

moving into apartment
Tech Stocks

Your TFSA Contribution Room Could Be Larger Than You Think

Shopify Inc (TSX:SHOP) stock has delivered large returns. Those who cashed out TFSA SHOP positions may have more room than…

Read more »

woman relaxes with phone
Dividend Stocks

BCE Cut its Dividend: Has the Stock Become a Better Income Investment?

BCE’s new payment offers income, but cash after spending still has to support the recovery.

Read more »

A chip in a circuit board says "AI"
Tech Stocks

Celestica Stock: Is AI Growth Worth the Risk in a Retirement Portfolio?

Celestica offers retirement growth potential, with a cash-flow trade-off that deserves more attention than sales alone.

Read more »